All lobbying filings

Capitol Counsel LLC

Capitol Counsel LLC filed a Q2 report for Biotechnology Innovation Organization (Formerly Biotechnology Industry ORG.) on July 21, 2025, reporting $50,000 in lobbying income.

Lobbying for Biotechnology Innovation Organization (Formerly Biotechnology Industry ORG.) · Represent organizations that promote research and support growth of biotechnology industry

As filed: CAPITOL COUNSEL LLC for BIOTECHNOLOGY INNOVATION ORGANIZATION (FORMERLY BIOTECHNOLOGY INDUSTRY ORG.).

All filings by Capitol Counsel LLC · Everything Biotechnology Innovation Organization (Formerly Biotechnology Industry ORG.) has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

CHARLES PATRICK MICHAELS New on this filing

Previously held: Chief of Staff, Deputy Chief of Staff, Legislative Director, Senior Legislative Assistant, and Legislative Assistant, Rep. David Schweikert; Staff Assistant, Rep. Ted Budd; Intern, Senator James DeMint.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Medicare/Medicaid

Medicare Part B coverage and reimbursement issues for biotechnology treatments and issues related to the Medicare Part D coverage, including issues found in H.R. 1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21

Taxation/Internal Revenue Code

Legislative and regulatory issues affecting innovation, including vaccines.

Trade (domestic/foreign)

Issues related to tarriffs.

Budget/Appropriations

Items related to USDA, FDA, genetic engineering, and regulations associated with biotechnology in the Agriculture/Rural Development/Food and Drug Administration proposed Appropriation measures for FY 2026 (House/Senate).

Health Issues

Public health issues impacting patient access to treatments. Updates and reforms to regulation of treatment development and research.

Bills named in this filing 1

H.R. 1
One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.